Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

148 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Eligibility NCT01246986 Carcinoma - Eligibility

- 27.09.21 - 1 Formular, 2 Itemgruppen, 27 Datenelemente, 2 Sprachen
Itemgruppen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01246986

Eligibility Advanced Adult Hepatocellular Carcinoma NCT02418988

- 27.09.21 - 1 Formular, 2 Itemgruppen, 19 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02418988

Eligibility Hepatocellular Carcinoma NCT00862082

- 27.09.21 - 1 Formular, 2 Itemgruppen, 19 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC); ODM derived from: https://clinicaltrials.gov/show/NCT00862082

Eligibility Hepatocellular Carcinoma NCT00669136

- 27.09.21 - 1 Formular, 2 Itemgruppen, 21 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00669136

Eligibility Hepatocellular Carcinoma NCT01686880

- 27.09.21 - 1 Formular, 2 Itemgruppen, 19 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver; ODM derived from: https://clinicaltrials.gov/show/NCT01686880

Eligibility Hepatocellular Carcinoma NCT02513199

- 27.09.21 - 1 Formular, 2 Itemgruppen, 17 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02513199

Eligibility Hepatocellular Carcinoma NCT02259647

- 27.09.21 - 1 Formular, 2 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02259647

Eligibility Hepatocellular Carcinoma NCT01658878

- 27.09.21 - 1 Formular, 3 Itemgruppen, 12 Datenelemente, 1 Sprache
Itemgruppen: Criteria, Inclusion Criteria, Exclusion Criteria
Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma); ODM derived from: https://clinicaltrials.gov/show/NCT01658878

Eligibility Hepatocellular Carcinoma NCT01575574

- 27.09.21 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis; ODM derived from: https://clinicaltrials.gov/show/NCT01575574

Eligibility Hepatocellular Carcinoma NCT01540461

- 27.09.21 - 1 Formular, 3 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Criteria, Inclusion Criteria, Exclusion Criteria
Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC); ODM derived from: https://clinicaltrials.gov/show/NCT01540461

Eligibility Hepatocellular Carcinoma NCT01570166

- 27.09.21 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01570166

Eligibility Hepatocellular Carcinoma NCT01643447

- 27.09.21 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC); ODM derived from: https://clinicaltrials.gov/show/NCT01643447

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video